Neumora reports promising Phase 1b results in Alzheimer’s agitation

Neumora Therapeutics, Inc. ( (NMRA) ) has provided an announcement.

On January 5, 2026, Neumora Therapeutics reported positive results from a Phase 1b signal-seeking study of NMRA-511, an oral, highly potent and selective vasopressin 1a receptor antagonist, in people with agitation associated with Alzheimer’s disease. The trial showed that NMRA-511 produced a clinically meaningful reduction in agitation symptoms on the Cohen-Mansfield Agitation Inventory, particularly in a pre-specified subgroup of patients with elevated baseline anxiety, while demonstrating a favorable safety and tolerability profile with mostly mild to moderate adverse events and low discontinuation rates. These findings, although from a study not powered for statistical significance, support further development of NMRA-511 and position Neumora to advance the program in 2026 through a multiple ascending dose extension at higher doses, formulation work toward once-daily extended-release dosing, and a planned Phase 2/3 dose-ranging study, potentially strengthening the company’s role in addressing the substantial unmet need in Alzheimer’s agitation treatment.

The most recent analyst rating on (NMRA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Neumora Therapeutics, Inc. stock, see the NMRA Stock Forecast page.

Spark’s Take on NMRA Stock

According to Spark, TipRanks’ AI Analyst, NMRA is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, large losses, and substantial cash burn), with bearish technicals reinforcing downside risk. Positive pipeline events provide some support, but they are early-stage and do not yet offset funding/dilution overhang; valuation metrics are limited due to negative earnings and no dividend.

To see Spark’s full report on NMRA stock, click here.

More about Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc., based in Watertown, Mass., is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain diseases. Its pipeline comprises seven programs targeting new mechanisms of action for a broad range of underserved, prevalent neuropsychiatric and neurodegenerative conditions, with the aim of improving treatment outcomes and quality of life for patients.

Average Trading Volume: 1,716,370

Technical Sentiment Signal: Sell

Current Market Cap: $277.4M

For detailed information about NMRA stock, go to TipRanks’ Stock Analysis page.